Fiche du document
2021
- doi: 10.3389/fonc.2021.704295
- issn: 2234-943X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3389/fonc.2021.704295
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34222029
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2234-943X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_E9DC9323568E2
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Mesothelium--TumorsCiter ce document
L. Gros et al., « Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases. », Serveur académique Lausannois, ID : 10.3389/fonc.2021.704295
Métriques
Partage / Export
Résumé
Mesothelioma is a malignancy of serosal membranes. Parietal pleura is the most common site, with peritoneum being the second most frequent location. Malignant peritoneal mesothelioma (MPM) is a rare and aggressive disease. The prognosis is often very poor with median overall survival ranging from 6 to 18 months in patients who are not candidates for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) due to non-resectable disease or comorbid conditions. For patients with resectable disease, CRS and HIPEC have become the standard of care. However, for patients with unresectable malignant mesothelioma there is unfortunately no effective systemic treatment beyond the first line. Based on the results of a recent phase II trial, lurbinectedin has clinical activity and acceptable toxicity in the second- and third-line treatment of malignant pleural mesothelioma. However, until present, no data have been available for patients with MPM and for patients who become refractory after multiple treatment lines. We report on two patients with metastatic MPM who achieved durable disease control of 10+ and 8 months with lurbinectedin in the fourth and fifth treatment line, respectively.